NATURE . COM {}

Analyzed Page
Matching Content Categories
CMS
Monthly Traffic Estimate
How Does Nature.com Make Money
How Much Does Nature.com Make
Keywords
Topics
Schema
Social Networks
External Links
Analytics And Tracking
Libraries
Hosting Providers
CDN Services

We are analyzing https://www.nature.com/articles/335440a0.

Title:
Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells | Nature
Description:
A common feature of follicular lymphoma, the most prevalent haematological malignancy in humans, is a chromosome translocation (t(14;18)) that has coupled the immunoglobulin heavy chain locus to a chromosome 18 gene denoted bcl-2 (refs 1–6). By analogy with the translocated c-myc oncogene in other B-lymphoid tumours (reviewed in ref. 7), bcl-2 is a candidate oncogene, but no biological effects of bcl-2 have yet been reported. To test whether bcl-2 influences the growth of haematopoietic cells, either alone or together with a deregulated c-myc gene, we have introduced a human bcl-2 complementary DNA (ref. 3) using a retroviral vector into bone marrow cells from either normal or Eµ-myc transgenic mice, in which B-lineage cells constitutively express the c-myc gene8–10. Bcl-2 cooperated with c-myc to promote proliferation of B-cell precursors, some of which became tumorigenic. To determine how bcl-2 expression impinges on growth factor requirements, the gene was introduced into a lymphoid and a myeloid cell line that require interleukin 3 (IL-3) (refs 11 and 12). In the absence of IL-3, bcl-2 promoted the survival of the infected cells but they persisted in a G0 state, rather than proliferating. These results argue that bcl-2 provided a distinct survival signal to the cell and may contribute to neoplasia by allowing a clone to persist until other oncogenes, such as c-myc, become activated.
Website Age:
30 years and 10 months (reg. 1994-08-11).

Matching Content Categories {📚}

Education
Telecommunications
Science

Content Management System {📝}

What CMS is nature.com built with?

Custom-built

No common CMS systems were detected on Nature.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of nature.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Nature.com Make Money? {💸}

Display Ads {🎯}

The website utilizes display ads within its content to generate revenue. Check the next section for further revenue estimates.

Ads are managed by yourbow.com. Particular relationships are as follows:

Direct Advertisers (10)

google.com, pmc.com, doceree.com, yourbow.com, audienciad.com, onlinemediasolutions.com, advibe.media, aps.amazon.com, getmediamx.com, onomagic.com

Reseller Advertisers (38)

conversantmedia.com, rubiconproject.com, pubmatic.com, appnexus.com, openx.com, smartadserver.com, lijit.com, sharethrough.com, video.unrulymedia.com, google.com, yahoo.com, triplelift.com, onetag.com, sonobi.com, contextweb.com, 33across.com, indexexchange.com, media.net, themediagrid.com, adform.com, richaudience.com, sovrn.com, improvedigital.com, freewheel.tv, smaato.com, yieldmo.com, amxrtb.com, adyoulike.com, adpone.com, criteo.com, smilewanted.com, 152media.info, e-planning.net, smartyads.com, loopme.com, opera.com, mediafuse.com, betweendigital.com

How Much Does Nature.com Make? {💰}

Display Ads {🎯}

$63,100 per month
Our analysis indicates Nature.com generates between $42,042 and $115,616 monthly online from display ads.

Keywords {🔍}

article, google, scholar, cas, nature, cell, bcl, access, cory, content, cmyc, cells, adams, pubmed, cookies, gene, oncogene, privacy, open, research, data, september, survival, ads, cancer, advertising, information, journal, subscribe, vaux, myeloid, institution, buy, death, croce, embo, schrader, molec, biol, dexter, metcalf, press, mulligan, permissions, essential, optional, media, personal, parties, policy,

Topics {✒️}

nature portfolio permissions reprints privacy policy cancer research vol medical research advertising subscribe nature social media nature 318 nature 303 nature 335 nature eµ-myc transgenic mice deregulated c-myc gene personal data springerlink instant access data protection permissions leukemia cancer cells anti-cancer effects myeloid cell line myeloid cell components translocated c-myc oncogene privacy distinct survival signal b-cell precursors b-cell malignancies bcl-2 expression impinges bcl-2 protein family explore content subscription content cell tissue kinet european economic area prevalent haematological malignancy institutional subscriptions read harcourt brace jovanovich eliza hall institute cellular mechanisms mediating dual–trigger release mesoporous silica nanospheres accepting optional cookies suzanne cory & jerry c-myc gene8–10 bone marrow cells journals search log b-lymphoid tumours issue learn savory essential oil manage preferences growth factor requirements

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells
         description:A common feature of follicular lymphoma, the most prevalent haematological malignancy in humans, is a chromosome translocation (t(14;18)) that has coupled the immunoglobulin heavy chain locus to a chromosome 18 gene denoted bcl-2 (refs 1â6). By analogy with the translocated c-myc oncogene in other B-lymphoid tumours (reviewed in ref. 7), bcl-2 is a candidate oncogene, but no biological effects of bcl-2 have yet been reported. To test whether bcl-2 influences the growth of haematopoietic cells, either alone or together with a deregulated c-myc gene, we have introduced a human bcl-2 complementary DNA (ref. 3) using a retroviral vector into bone marrow cells from either normal or EÂµ-myc transgenic mice, in which B-lineage cells constitutively express the c-myc gene8â10. Bcl-2 cooperated with c-myc to promote proliferation of B-cell precursors, some of which became tumorigenic. To determine how bcl-2 expression impinges on growth factor requirements, the gene was introduced into a lymphoid and a myeloid cell line that require interleukin 3 (IL-3) (refs 11 and 12). In the absence of IL-3, bcl-2 promoted the survival of the infected cells but they persisted in a G0 state, rather than proliferating. These results argue that bcl-2 provided a distinct survival signal to the cell and may contribute to neoplasia by allowing a clone to persist until other oncogenes, such as c-myc, become activated.
         datePublished:
         dateModified:
         pageStart:440
         pageEnd:442
         sameAs:https://doi.org/10.1038/335440a0
         keywords:
            Science
            Humanities and Social Sciences
            multidisciplinary
         image:
         isPartOf:
            name:Nature
            issn:
               1476-4687
               0028-0836
            volumeNumber:335
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Nature Publishing Group UK
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:David L. Vaux
               affiliation:
                     name:PO Royal Melbourne Hospital
                     address:
                        name:The Walter and Eliza Hall Institute of Medical Research, PO Royal Melbourne Hospital, Australia
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Suzanne Cory
               affiliation:
                     name:PO Royal Melbourne Hospital
                     address:
                        name:The Walter and Eliza Hall Institute of Medical Research, PO Royal Melbourne Hospital, Australia
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jerry M. Adams
               affiliation:
                     name:PO Royal Melbourne Hospital
                     address:
                        name:The Walter and Eliza Hall Institute of Medical Research, PO Royal Melbourne Hospital, Australia
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells
      description:A common feature of follicular lymphoma, the most prevalent haematological malignancy in humans, is a chromosome translocation (t(14;18)) that has coupled the immunoglobulin heavy chain locus to a chromosome 18 gene denoted bcl-2 (refs 1â6). By analogy with the translocated c-myc oncogene in other B-lymphoid tumours (reviewed in ref. 7), bcl-2 is a candidate oncogene, but no biological effects of bcl-2 have yet been reported. To test whether bcl-2 influences the growth of haematopoietic cells, either alone or together with a deregulated c-myc gene, we have introduced a human bcl-2 complementary DNA (ref. 3) using a retroviral vector into bone marrow cells from either normal or EÂµ-myc transgenic mice, in which B-lineage cells constitutively express the c-myc gene8â10. Bcl-2 cooperated with c-myc to promote proliferation of B-cell precursors, some of which became tumorigenic. To determine how bcl-2 expression impinges on growth factor requirements, the gene was introduced into a lymphoid and a myeloid cell line that require interleukin 3 (IL-3) (refs 11 and 12). In the absence of IL-3, bcl-2 promoted the survival of the infected cells but they persisted in a G0 state, rather than proliferating. These results argue that bcl-2 provided a distinct survival signal to the cell and may contribute to neoplasia by allowing a clone to persist until other oncogenes, such as c-myc, become activated.
      datePublished:
      dateModified:
      pageStart:440
      pageEnd:442
      sameAs:https://doi.org/10.1038/335440a0
      keywords:
         Science
         Humanities and Social Sciences
         multidisciplinary
      image:
      isPartOf:
         name:Nature
         issn:
            1476-4687
            0028-0836
         volumeNumber:335
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Nature Publishing Group UK
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:David L. Vaux
            affiliation:
                  name:PO Royal Melbourne Hospital
                  address:
                     name:The Walter and Eliza Hall Institute of Medical Research, PO Royal Melbourne Hospital, Australia
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Suzanne Cory
            affiliation:
                  name:PO Royal Melbourne Hospital
                  address:
                     name:The Walter and Eliza Hall Institute of Medical Research, PO Royal Melbourne Hospital, Australia
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jerry M. Adams
            affiliation:
                  name:PO Royal Melbourne Hospital
                  address:
                     name:The Walter and Eliza Hall Institute of Medical Research, PO Royal Melbourne Hospital, Australia
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Nature
      issn:
         1476-4687
         0028-0836
      volumeNumber:335
Organization:
      name:Nature Publishing Group UK
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:PO Royal Melbourne Hospital
      address:
         name:The Walter and Eliza Hall Institute of Medical Research, PO Royal Melbourne Hospital, Australia
         type:PostalAddress
      name:PO Royal Melbourne Hospital
      address:
         name:The Walter and Eliza Hall Institute of Medical Research, PO Royal Melbourne Hospital, Australia
         type:PostalAddress
      name:PO Royal Melbourne Hospital
      address:
         name:The Walter and Eliza Hall Institute of Medical Research, PO Royal Melbourne Hospital, Australia
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:David L. Vaux
      affiliation:
            name:PO Royal Melbourne Hospital
            address:
               name:The Walter and Eliza Hall Institute of Medical Research, PO Royal Melbourne Hospital, Australia
               type:PostalAddress
            type:Organization
      name:Suzanne Cory
      affiliation:
            name:PO Royal Melbourne Hospital
            address:
               name:The Walter and Eliza Hall Institute of Medical Research, PO Royal Melbourne Hospital, Australia
               type:PostalAddress
            type:Organization
      name:Jerry M. Adams
      affiliation:
            name:PO Royal Melbourne Hospital
            address:
               name:The Walter and Eliza Hall Institute of Medical Research, PO Royal Melbourne Hospital, Australia
               type:PostalAddress
            type:Organization
PostalAddress:
      name:The Walter and Eliza Hall Institute of Medical Research, PO Royal Melbourne Hospital, Australia
      name:The Walter and Eliza Hall Institute of Medical Research, PO Royal Melbourne Hospital, Australia
      name:The Walter and Eliza Hall Institute of Medical Research, PO Royal Melbourne Hospital, Australia
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

Social Networks {👍}(2)

External Links {🔗}(77)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Prism.js
Zoom.js

Emails and Hosting {✉️}

Mail Servers:

mxa-002c5801.gslb.pphosted.com
mxb-002c5801.gslb.pphosted.com

Name Servers:

pdns1.ultradns.net
pdns2.ultradns.net
pdns3.ultradns.org
pdns4.ultradns.org
pdns5.ultradns.info
pdns6.ultradns.co.uk

CDN Services {📦}

Crossref

4.74s.